Search Content | UT Health San Antonio MD Anderson Cancer Center

Search Result for "*:*"

Clinical Trial

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB--A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors (CTMS# 21-0064)

Clinical Trial

Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia (CTMS# 21-0097)

Clinical Trial

ML/AI algorithms to enable precise quantification of histologic and immunohistochemical parameters for cancer detections and treatment

Clinical Trial

EA8191: Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE). (CTMS# 21-0109)

Clinical Trial

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] (CTMS# 21-0114)

Clinical Trial

A Multicenter Phase 1 Study to Determine the Maximum Tolerated Dose/ Maximum Feasible Dose, Safety, and Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered via Intraventricular Catheter for Leptomeningeal Metastases (CTMS# 21-0138)

This is an open-label, multicenter, Phase 1 dose-escalation study to establish the safety and tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) and to identify a maximum tolerated dose (MTD) and/or maximum feasible dose (MFD).

Clinical Trial

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC

Clinical Trial

ACNS2021: A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (CTMS# 21-0140)

Clinical Trial

daNIS-3: An Open-Label, Multi-Center, Phase II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With Standard of Care (SOC) Anti-Cancer Therapy for the Second Line Treatment of Metastatic Colorect

This study evaluates the preliminary efficacy and safety of NIS793 and other novel investigational combinations with SOC anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of metastatic colorectal cancer.

Clinical Trial